Please login to the form below
Rebiotix
This page shows the latest Rebiotix news and features for those working in and with pharma, biotech and healthcare.
Finch Therapeutics bags $53m for microbiome therapies
in 2017 rival Rebiotix presented early data showing that its microbiota suspension RBX2660 prevents recurrences of C. ... Diff candidate. Like Finch, Rebiotix received a BTD from the FDA, and both companies have products in phase 3 clinical trials,
Latest news
-
Finch’s microbiota drug for C. diff gets FDA breakthrough status
tries to bring the drug to market ahead of rival microbiota products from Ferring/Rebiotix and Takeda/NuBiyota. ... In 2017, Rebiotix reported positive results from an open-label trial of its candidate RBX2660, which is given in two separate doses a
-
Microbiome specialist Rebiotix chalks up C. diff trial success
Almost 79% of patients on Rebiotix's therapy had no recurrence over the course of the study, which compares favourably with a historical control rate of 52% says the company. ... Rebiotix's chief executive Lee Jones said the results suggest that a
-
After delay, Merck gets US approval for serious infection drug
adjunctive therapy category from the likes of Seres Therapeutics' SER-109 and Rebiotix' RBX2660.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
The Creative Engagement Group
We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
